Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JSKN033 + platinum
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
JSKN033 + platinum is a combination therapy being developed by Jiangsu Alphamab Biopharmaceuticals for the treatment of advanced cervical cancer. JSKN033 is a proprietary high-concentration subcutaneous co-formulation consisting of an anti-HER2 bispecific antibody-drug conjugate (ADC), JSKN003, and a PD-L1 immune checkpoint inhibitor, envafolimab. JSKN003 targets two non-overlapping epitopes of the HER2 extracellular domain and is conjugated to a topoisomerase I inhibitor payload via a cleavable linker. Envafolimab is a single-domain antibody targeting PD-L1. This combination is being evaluated alongside platinum-based chemotherapy (such as cisplatin or carboplatin) as a first-line treatment to leverage the synergistic effects of HER2-targeted cytotoxicity, immune checkpoint blockade, and DNA-damaging chemotherapy.
- Other names
- JSKN033 in combination with platinum-based chemotherapyJSKN-033 in combination with platinum-based chemotherapyJSKN 033 in combination with platinum-based chemotherapy
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on JSKN033 + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JSKN033 + platinum.